July 14, 2022

Focused Ultrasound to Open the Blood-Brain Barrier in Recurrent Glioblastoma (Podcast)

The rationale and promise of a new method to enable chemotherapy delivery

Glioblastoma is notorious for being therapeutically elusive. One key challenge is getting chemotherapies past the blood-brain barrier to target glioblastoma’s highly infiltrative tumors.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Some of the drugs that work very well against cancers outside the brain just can’t get into the brain,” says Glen Stevens, DO, PhD, Section Head of Adult Neuro-Oncology at Cleveland Clinic. “We realized we needed to look at ways to allow us to deliver chemotherapies into the brain.”

A leading candidate is the use of low-intensity focused ultrasound (LIFU) to open the blood-brain barrier for this purpose. That application of LIFU is the focus of a newly completed phase 1 study that Dr. Stevens is helping to lead — and also the focus of the latest episode of Cleveland Clinic’s Cancer Advances podcast, which features Dr. Stevens as its guest expert.

In the podcast, Dr. Stevens explores the following:

Advertisement
  • The essentials of glioblastoma and why it is so difficult to treat
  • How LIFU works and the rationale for its use to disrupt the blood-brain barrier
  • The phase 1 trial studying LIFU to enable delivery of carboplatin to the brains of adults with recurrent glioblastoma
  • Next steps in the research of LIFU for glioblastoma therapy

Click the podcast player above to listen to the 29-minute episode now, or read on for a short edited excerpt.

Excerpt from the episode

Dr. Stevens: We are going to be starting a new trial in glioblastoma patients where we will be using something called 5-ALA, or 5-aminolevulinic acid. It’s a drug that’s used in neurosurgery to light up glioblastoma — it’s taken into the tumor and you can fluoresce it so you can see where it is. You can use photodynamic therapy to affect the oxygenation and kill cells; it’s used in dermatology.

There is some preliminary data looking at using it with sonication, taking this 5-ALA and then, through sonication, using it to kill glioblastoma cells. We have just gotten IRB approval and hope to put our first patient in the trial very soon.

Advertisement

Related Articles

Cleveland Clinic physiatrist
March 22, 2024
The Vital Role of Oncology Rehabilitation (Podcast)

New program provides prehabilitation and rehabilitation services to help patients with cancer maintain and regain function

Doctors working on MGUS screening study
March 18, 2024
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

Ad